Myeloproliferative disease : subject feeds
GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
The role of JAK inhibitors in hematopoietic cell transplantation
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort
Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Second versus first wave of COVID-19 in patients with MPN
Life histories of myeloproliferative neoplasms inferred from phylogenies
Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries
A new standard for mastocytosis
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models
Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
Feed Fetched by RSS Dog.